Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL9659958 | 0.82 | LMNA (0.43) | LMNATSHRSMN1; SMN2 | |
| Isobutyraldehyde SCHEMBL427264 | 0.82 | LMNA (0.67) | LMNATHRB | |
| SCHEMBL11769218 | 0.80 | LMNA (0.63) | LMNATHRB | |
| SCHEMBL11338287 | 0.80 | LMNA (0.63) | LMNATHRB | |
| Acetaldehyde SCHEMBL212729 | 0.79 | LMNA (0.71) | LMNATSHRTHRB | |
| SCHEMBL4293299 | 0.79 | LMNA (0.71) | LMNATHRB | |
| SCHEMBL29715 | 0.79 | — | — | |
| Ethylene Glycol SCHEMBL14689834 | 0.78 | TSHR (0.61) | LMNATSHRSMN1; SMN2 | |
| SCHEMBL5582150 | 0.78 | LMNA (0.60) | LMNATSHRTHRB | |
| SCHEMBL401436 | 0.78 | LMNA (0.60) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006119104-A2 | PROCESS FOR PREPARING ISATINS WITH CONTROL OF SIDE-PRODUCT FORMATION | WYETH (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060247442-A1 | Process for preparing isatins with control of side-product formation | WYETH (US) | 2006-11-02 | — | — | US | claimed |
| US-20100221445-A1 | O-DESMETHYLVENLAFAXINE AND BAZEDOXIFENE COMBINATION PRODUCT AND USES THEREOF | WYETH LLC (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2006119104-A2 | PROCESS FOR PREPARING ISATINS WITH CONTROL OF SIDE-PRODUCT FORMATION | WYETH (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247442-A1 | Process for preparing isatins with control of side-product formation | WYETH (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221445-A1 | O-DESMETHYLVENLAFAXINE AND BAZEDOXIFENE COMBINATION PRODUCT AND USES THEREOF | CYP19A1, HSD17B11, SLC6A4 | LMNA 2634/4885TSHR 751/4885SMN1; SMN2 1541/4885 |
| US-20060247442-A1 | Process for preparing isatins with control of side-product formation | NISCH, HASPIN, INMT | LMNA 2242/4885TSHR 2552/4885SMN1; SMN2 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.